Mirum Pharmaceuticals shares rise on successful Phase 3 trial for liver disease treatment
MIRM Mirum Pharmaceuticals Inc
$80.14 -2.73%
View chart & analysis → - 1Mirum Pharmaceuticals shares rose 2.9% in pre-market trading.
- 2Clinical results confirmed a relative reduction in serum bile acids of 69.0% compared to placebo.
- 3Mirum Pharmaceuticals plans to submit a supplemental New Drug Application to the US FDA in the first half of 2027.
So what's the key point?
Mirum Pharmaceuticals obtained positive results in a liver disease treatment trial. The company plans to apply for drug approval in the US during the first half of 2027.
Source Investing.com +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.